Long‐term bone marrow cultured stromal cells regulate myeloma tumour growthin vitro: studies with primary tumour cells and LTBMC‐dependent cell lines
- 1 January 1998
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 100 (1) , 166-175
- https://doi.org/10.1046/j.1365-2141.1998.00517.x
Abstract
Long-term bone marrow cultured stromal cells (LTBMC) produce IL-6 after contact with tumour cells from multiple myeloma patients. We found that LTBMC could substitute for exogenous IL-6 in the stimulation of bone marrow plasma cells from myeloma patients with active disease in short-term cultures. In addition, tumour cells of some patients with inactive disease, which were unresponsive to exogenous IL-6, were induced to IL-6-dependent growth after LTBMC co-culture. To study the role of LTBMC in myeloma tumour growth in vitro, plasma cell lines UM-2 and UM-3 were selected. UM-2 and UM-3 grew in contact with LTBMC and proliferation was blocked by antibodies against IL-6, IL-6 receptor (IL-6R, gp80, CD126) or the common signal transducing unit, gp130 (CD130). Culture with IL-6 alone or combined with GM-CSF resulted in cell death via apoptosis. The combination of IL-6 with soluble gp80, however, maintained in vitro proliferation of UM-2 and UM-3 cells. These data imply that LTBMC regulate myeloma growth in vitro via production of IL-6, possibly via induction of a functional IL-6 receptor on the tumour cells.Keywords
This publication has 36 references indexed in Scilit:
- Establishment and characterization of a human stroma-dependent myeloma cell line (MM5.1) and its stroma-independent variant (MM5.2)Leukemia, 1997
- Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl.The Journal of Experimental Medicine, 1995
- Interleukin-6 Inhibits Apoptosis of Malignant Plasma CellsCellular Immunology, 1995
- In vitro culture of primary plasmacytomas requires stromal cell feeder layers.Proceedings of the National Academy of Sciences, 1993
- Association of recombinant soluble IL-6-signal transducer, gp130, with a complex of IL 6 and soluble IL-6 receptor, and establishment of an ELISA for soluble gp130Immunology Letters, 1992
- Conformations of immunoglobulin hypervariable regionsNature, 1989
- Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.Journal of Clinical Investigation, 1989
- Phenotypical and Functional Characterization of the Idiotype‐Positive Blood B Cells in Multiple MyelomaScandinavian Journal of Immunology, 1988
- Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomasNature, 1988
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975